Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Keith March

Cardiovascular Disease Gainesville, FL Medical Doctor

NPI 1023073681 CMS profile 876021

1601 Sw Archer Rd, Gainesville, FL 32608

Open in the dashboard

General payments

$176,103

105 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Keith March of Gainesville, FL is reported in the CMS Open Payments database as having received $176,103 across 105 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 97th percentile of Cardiovascular Disease profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $137 1
2024 General $2,188 1
2023 General $60,258 22
2022 General $47,659 48
2021 General $8,428 13
2020 General $57,347 19
2019 General $86 1

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Keith March
  • Cardiovascular Disease median
  • Middle half of Cardiovascular Disease
  • National median

In program year 2025, general payments to Keith March were reported at $137. Among 16,617 Cardiovascular Disease profiles paid that year, the median was $432 and the middle half received between $132 and $1,252.

Show as a table
Year Keith March Cardiovascular Disease median Middle half National median
2019 $86 $450 $127–$1,392 $163
2020 $57,347 $242 $77–$751 $114
2021 $8,428 $335 $101–$1,037 $132
2022 $47,659 $395 $121–$1,211 $149
2023 $60,258 $443 $136–$1,283 $160
2024 $2,188 $450 $136–$1,323 $164
2025 $137 $432 $132–$1,252 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Arthrex, Inc. $175,711 100 payments
  2. Argenx US, Inc. $137 1 payment
  3. Sientra, Inc. $112 2 payments
  4. Sanara MedTech Inc. $79 1 payment
  5. Genzyme Corporation $63 1 payment

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Consulting Fee $154,385 35 payments
  2. Travel and Lodging $13,610 20 payments
  3. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $6,235 1 payment
  4. Food and Beverage $1,873 49 payments
Products named General payments · program years 2019–2025
  1. OTHER OTHER OTHER OTHER $26,535 1 payment
  2. BIOLOGICS CONSUMABLES SOFT TISSUE REPAIR AMNION $2,813 1 payment
  3. ARTHREX $832 7 payments
  4. BIOLOGICS CONSUMABLES AUTOLOGOUS BLOOD PRODUCTS BONE MARROW $144 3 payments
  5. VYVGART Hytrulo $137 1 payment
  6. SIENTRA HIGH STRENGTH COHESIVE SILICONE GEL BREAST IMPLANT $112 2 payments
  7. BIOLOGICS CONSUMABLES BONE REPAIR IOBP $87 1 payment
  8. CellerateRx $79 1 payment
  9. FABRAZYME $63 1 payment

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Records

105 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Cardiovascular Disease in Florida

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record